Apogee Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026A major acquisition can significantly change stock value and company direction, affecting shareholders' investments.
New partnerships can help develop new drugs and create value for investors.
Board elections and auditor selection ensure proper oversight of company management and finances.
Major outside investment signals confidence in the drug's potential and provides cash for development.
Good clinical trial results increase the chance a drug reaches patients and generates future revenue.
Quarterly earnings show if the company is progressing toward profitability and managing cash well.
Stocky reads Apogee Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Apogee Therapeutics, Inc.'s most recent tracked filing was a 8-K on 22 Jun 2026: AbbVie agrees to acquire Apogee Therapeutics for undisclosed price.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.